SYNOPHYLATE Drug Patent Profile
✉ Email this page to a colleague
When do Synophylate patents expire, and when can generic versions of Synophylate launch?
Synophylate is a drug marketed by Cent Pharms and is included in one NDA.
The generic ingredient in SYNOPHYLATE is theophylline sodium glycinate. There are thirty-six drug master file entries for this compound. Additional details are available on the theophylline sodium glycinate profile page.
Summary for SYNOPHYLATE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 171 |
Patent Applications: | 6,962 |
Formulation / Manufacturing: | see details |
DailyMed Link: | SYNOPHYLATE at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for SYNOPHYLATE
US Patents and Regulatory Information for SYNOPHYLATE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cent Pharms | SYNOPHYLATE | theophylline sodium glycinate | ELIXIR;ORAL | 006333-008 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |